Tacket Carol O, Sztein Marcelo B, Losonsky Genevieve A, Wasserman Steven S, Estes Mary K
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Clin Immunol. 2003 Sep;108(3):241-7. doi: 10.1016/s1521-6616(03)00120-7.
Norwalk virus-like particles (VLPs), made from recombinant capsid protein, are a promising vaccine. Thirty-six healthy adult volunteers received 250 microg (n = 10), 500 microg (n = 10), or 2000 microg (n = 10) of orally administered VLP or placebo (n = 6). All vaccinees developed significant rises in IgA anti-VLP antibody-secreting cells. Ninety percent who received 250 microg developed rises in serum anti-VLP IgG; neither the rates of seroconversion nor geometric mean titers increased at the higher doses. About 30-40% of volunteers developed mucosal anti-VLP IgA. Lymphoproliferative responses and IFN-gamma production were observed transiently among those who received 250 microg or 500 microg but not 2000 microg of VLP. Studies to increase immunogenicity using a mucosal adjuvant are planned.
由重组衣壳蛋白制成的诺如病毒样颗粒（VLPs）是一种很有前景的疫苗。36名健康成年志愿者分别口服250微克（n = 10）、500微克（n = 10）或2000微克（n = 10）的VLP或安慰剂（n = 6）。所有接种疫苗者分泌IgA抗VLP抗体的细胞均显著增多。接受250微克疫苗的志愿者中有90%血清抗VLP IgG升高；更高剂量组的血清转化率和几何平均滴度均未增加。约30 - 40%的志愿者产生了黏膜抗VLP IgA。在接受250微克或500微克而非2000微克VLP的志愿者中，短暂观察到淋巴细胞增殖反应和IFN-γ产生。计划开展使用黏膜佐剂提高免疫原性的研究。
